Allotex Inc. is an ophthalmic biologics and device company developing new therapeutic solutions for the treatment of presbyopia, hyperopia, and myopia. The therapy is accomplished through tissue addition technology that uses precisely-shaped human corneal allografts to create what is essentially a permanent, living contact lens or lens insert.
Allotex is a start-up company led by Drs. David Muller and Michael Mrochen.